TargetBeta
CFTR
CF transmembrane conductance regulator · also MRP7, ABC35, TNR-CFTR, dJ760C5.1 · Chloride channels, ATP-gated CFTR
3 programs in company-led studies act on CFTR, from 1 company: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ivacaftorrule | Vertex Pharmaceuticals | phase 4 | 784 running | – | ChEMBL |
| lumacaftorrule | Vertex Pharmaceuticals | phase 4 | 231 running | – | ChEMBL |
| tezacaftorrule | Vertex Pharmaceuticals | phase 3 | 394 running | – | ChEMBL |
Conditions their studies are in
- Cystic Fibrosis, 3 programs
- Ciliary Motility Disorders, 1 program
- Cognitive Dysfunction, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 6, 2027ivacaftor · Vertex Pharmaceuticals · phase 4 · NCT05331183
- Apr 6, 2027tezacaftor · Vertex Pharmaceuticals · phase 3 · NCT05331183
- May 2027lumacaftor · Vertex Pharmaceuticals · phase 4 · NCT07695090
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.